|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Identical BRAF V600E and telomerase reverse transcriptase promoter mutations were identified in both the original and recurrent tumor.
|
29620581 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Identical BRAF V600E and telomerase reverse transcriptase promoter mutations were identified in both the original and recurrent tumor.
|
29620581 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The primary and recurrent tumors both harbored the BRAF V600E mutation, and the recurrent tumor was immunonegative for ATRX.
|
28185325 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The primary and recurrent tumors both harbored the BRAF V600E mutation, and the recurrent tumor was immunonegative for ATRX.
|
28185325 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The tumor showed necrosis and the BRAF V600E mutation on histological examination, with no evidence of tumor recurrence 1 year after gross-total resection.
|
27015517 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations are associated with aggressive thyroid tumor characteristics, tumor recurrence and patient mortality as well as BRAF V600E</span> mutation.
|
26733501 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The tumor showed necrosis and the BRAF V600E mutation on histological examination, with no evidence of tumor recurrence 1 year after gross-total resection.
|
27015517 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TERT promoter mutations are associated with aggressive thyroid tumor characteristics, tumor recurrence and patient mortality as well as BRAF V600E</span> mutation.
|
26733501 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Decreased CPSF2 gene expression was associated with shorter disease-free survival (P = .03), large tumor size (T3 and T4) (P = .03), tumor recurrence (P < .01), and mortality (P < .01), independent of BRAF V600E mutation status.
|
24654752 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Decreased CPSF2 gene expression was associated with shorter disease-free survival (P = .03), large tumor size (T3 and T4) (P = .03), tumor recurrence (P < .01), and mortality (P < .01), independent of BRAF V600E mutation status.
|
24654752 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genetic analyses revealed amplification of the BRAF gene in both the primary cerebellar pilocytic astrocytoma and the recurrent tumor with biphasic features, as well as a BRAF V600E missense mutation in the oligodendroglioma-like component.
|
23082883 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although multivariate analysis showed that tumor recurrence was not associated with BRAF(V600E) mutation, it has not been shown that treating these patients more aggressively changes outcomes.
|
23370668 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genetic analyses revealed amplification of the BRAF gene in both the primary cerebellar pilocytic astrocytoma and the recurrent tumor with biphasic features, as well as a BRAF V600E missense mutation in the oligodendroglioma-like component.
|
23082883 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although multivariate analysis showed that tumor recurrence was not associated with BRAF(V600E) mutation, it has not been shown that treating these patients more aggressively changes outcomes.
|
23370668 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The proportion of BRAF(V600E) mutation was significantly associated with the number of high-risk factors of tumor recurrence (P < 0.001).
|
22190222 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The proportion of BRAF(V600E) mutation was significantly associated with the number of high-risk factors of tumor recurrence (P < 0.001).
|
22190222 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition to the diagnostic use, BRAF V600E mutation can also be used for tumor prognostication, as this mutation is associated with higher rate of tumor recurrence and tumor-related mortality.
|
21526955 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition to the diagnostic use, BRAF V600E mutation can also be used for tumor prognostication, as this mutation is associated with higher rate of tumor recurrence and tumor-related mortality.
|
21526955 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Most clinical studies have demonstrated an association of BRAF(V600E) mutation with aggressive clinicopathologic characteristics and high tumor recurrence, although the results are controversial.
|
20230995 |
2010 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Most clinical studies have demonstrated an association of BRAF(V600E) mutation with aggressive clinicopathologic characteristics and high tumor recurrence, although the results are controversial.
|
20230995 |
2010 |
|
rs16949649
|
|
|
0.010 |
GeneticVariation |
BEFREE |
TT genotype at rs16949649 and CC genotype at rs2302254 were associated with higher rates of tumors larger than 20 mm, Ki67 LI and tumor recurrence.
|
31734851 |
2020 |
|
rs2302254
|
|
|
0.010 |
GeneticVariation |
BEFREE |
TT genotype at rs16949649 and CC genotype at rs2302254 were associated with higher rates of tumors larger than 20 mm, Ki67 LI and tumor recurrence.
|
31734851 |
2020 |
|
rs121434592
|
|
|
0.010 |
GeneticVariation |
BEFREE |
One patient harbored an AKT1 E17K mutation in the recurrent tumor, whereas PIK3CA E542K and E88Q mutations were detected in the primary and untreated metastatic tumor samples.
|
30898102 |
2019 |
|
rs747489687
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The MCPH1 p.Arg304ValfsTer3 carrier breast tumors showed recurrent tumor suppressor gene TP53 mutations, which were also significantly over-represented in breast tumors with somatically inactivated MCPH1.
|
30809794 |
2019 |
|
rs1056892
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results suggest that NOS3 895G>T and CBR3 730G>A are genetic markers that can be used to predict tumor recurrence in NMIBC patients receiving intravesical instillations of THP.
|
30125887 |
2018 |